|Podcasts|April 25, 2019
Episode 30: Challenges in Renal Disease Drug Development
Author(s)Lisa Henderson, Christen Harm
Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease.
Advertisement
Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease. This podcast was brought to you by
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Elicio Therapeutics’ Shares Drop Following Announcement of Phase II Trial Results
2
Novavax's Strategy Across Commercial, R&D, and Partnerships
3
Partnering in Non-Opioids: Q&A with Dr. Edward Littler and Dave Watson
4
FDA Approves Skinvive by Juvéderm for Improvement of Neck Appearance
5